PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33809580-1	2021	The approval of Bruton"s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib and the Bcl-2 inhibitor venetoclax have revolutionized the treatment of chronic lymphocytic leukemia (CLL).	ibrutinib	66-75	Bruton tyrosine kinase	Homo sapiens	16-40	
33809580-1	2021	The approval of Bruton"s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib and the Bcl-2 inhibitor venetoclax have revolutionized the treatment of chronic lymphocytic leukemia (CLL).	ibrutinib	66-75	Bruton tyrosine kinase	Homo sapiens	42-45